Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agere Expands cGMP Spray Dry Manufacturing Capabilities

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
Solubility CRO/CMO now supports clients from formulation design through phase IIb manufacturing.

Agere Pharmaceuticals, Inc. has announced that it has added the capability to support clients entering Phase IIb clinical trials with cGMP manufacturing.

The new capacity extends the services to pharmaceutical companies that currently partner with Agere for formulation development to improve oral bioavailability of their BCS II and IV compounds.

By expanding cGMP manufacturing services, Agere now offers its clients one-stop-shopping from concept development through manufacturing for advanced clinical trials.

Outsourcing research and development to CROs is a widespread and growing practice for pharmaceutical and biotechnology companies.

The trend toward relying on a single service provider for research into clinical trial manufacturing eliminates costs, delays and risks inherent in switching vendors.

“We’ve extended our cGMP spray drying capabilities in response to our clients’ requests to continue with Agere as they enter Phase IIb clinical trials,” commented Marshall Crew, Agere’s President and CEO. “This is a natural progression for us, as expanding services delivers efficiencies to our clients.”

Pharmaceutical companies facing solubility challenges with active pharmaceutical ingredients (APIs) depend on Agere’s expertise and scientific approach to enhance the bioavailability of their drugs.

Agere services span formulation design and development into clinical trial drug product manufacturing. All services are offered “à la carte,” allowing companies the flexibility to engage with Agere at any stage in their process.

Agere provides all services on a fee-for-service basis, in which Agere assumes no intellectual property (IP) ownership over work done on behalf of the company’s clients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!